Sangamo Therapeutics, Inc. [NASDAQ: SGMO] gained by 0.56% on the last trading session, reaching $11.66 price per share at the time. Sangamo Therapeutics, Inc. represents 115.71M in outstanding shares, while the company has a total market value of $1.35B with the latest information.

The Sangamo Therapeutics, Inc. traded at the price of $11.66 with 1.95 million shares were bought and sold during the latest trading session. Over the period of the last 3 months, the average trading volume of SGMO shares recorded 1.20M.

Sangamo Therapeutics, Inc. [NASDAQ:SGMO]: Analyst Rating and Earnings

Its stock price has been found in the range of 6.26 to 13.91. This is compared to its latest closing price of $11.60.

Keep your eyes peeled for the next scheduled financial results to be made public for this company, which are scheduled to be released on Thu 27 Feb (In 81 Days).

Fundamental Analysis of Sangamo Therapeutics, Inc. [SGMO]

Now let’s turn to look at profitability: with a current Operating Margin for Sangamo Therapeutics, Inc. [SGMO] sitting at -88.87.

This company’s Return on Total Capital is -24.70, and its Return on Invested Capital has reached -21.10%. Its Return on Equity is -24.65, and its Return on Assets is -15.58. These metrics suggest that this Sangamo Therapeutics, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, Sangamo Therapeutics, Inc. [SGMO] has generated a Total Debt to Total Equity ratio of 7.55. Similarly, its Total Debt to Total Capital is 7.02, while its Total Debt to

Total Assets stands at 4.69.

What about valuation? This company’s Enterprise Value to EBITDA is -13.47. The Enterprise Value to Sales for this firm is now 13.16, and its Total Debt to Enterprise Value stands at 0.04. Sangamo Therapeutics, Inc. [SGMO] has a Price to Book Ratio of 3.20, a Price to Cash Flow Ratio of 29.95.

Shifting the focus to workforce efficiency, Sangamo Therapeutics, Inc. [SGMO] earns $279,642 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 19.57 and its Total Asset Turnover is 0.19. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 5.23 and its Current Ratio is 5.23. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Sangamo Therapeutics, Inc. [SGMO] has 115.71M shares outstanding, amounting to a total market cap of $1.35B. Its stock price has been found in the range of 6.26 to 13.91. At its current price, it has moved down by -16.18% from its 52-week high, and it has moved up 86.26% from its 52-week low.

This stock’s Beta value is currently 2.85, which indicates that it is 4.33% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 79.22. This RSI suggests that Sangamo Therapeutics, Inc. is currently Overbought.

Conclusion: Is Sangamo Therapeutics, Inc. [SGMO] a Reliable Buy?

Shares of Sangamo Therapeutics, Inc. [SGMO], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.